ZAMBIA CHOLERA VACCINES MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

A cholera vaccine is a vaccine that is effective in preventing cholera. Cholera is spread through contaminated food or water. It is not usually spread directly from person to person, but it can be spread through contact with the feces of an infected person. Cholera causes severe diarrhea and vomiting. If it is not treated quickly, it can lead to dehydration and even death. Cholera is caused by Vibrio cholerae and epidemics that are primarily caused by serogroups O1 and O139. Serogroup O1 has two biotypes (El Tor and classical) and both biotypes can further be classified into three serotypes: Ogawa, Inaba and Hikojima. V. cholerae O1 Hikojima is an unstable form and rarely occurs in nature. The recommended cholera vaccines are administered orally to elicit a protective local mucosal immune response in the gut, which was poorly achieved with the injectable vaccines that were used until the 1970s. The first effective oral cholera vaccine was Dukoral, developed in Sweden in the 1980s. For the public health use of modern cholera vaccines in developing countries, it is important to distinguish between endemic and epidemic cholera. For the control of epidemic cholera, selective vaccination of populations at a definably high risk of an epidemic, or reactive vaccination shortly after the onset of the epidemic, can be considered.

Market Dynamics:

Increasing prevalence of cholera is expected to drive the growth of the Zambia cholera vaccines market over the forecast period. For instance, on January 16, 2024, according to data published by U.S. EMBASSY IN ZAMBIA, since October 2023, in Zambia, there have been 8,276 cumulative cholera cases, with 333 deaths, and a case fatality rate of 4% which is four times the World Health Organization (WHO) threshold.

Key Features of the Study:

• This report provides an in-depth analysis of the Zambia cholera vaccines market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2024–2031), considering 2023 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Zambia cholera vaccines market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Biovac Inc., Valneva SE., EMERGENT, Astellas Pharma Inc, Sanofi, EUBIOLOGICS CO., LTD,Johnson & Johnson Services Inc., and Celldex Therapeutics.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Zambia cholera vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Zambia cholera vaccines market

Detailed Segmentation:

• Zambia Cholera Vaccines Market, By Product
• • Dukoral
  • Shanchol
  • Vaxchora
  • Euvichol & Euvichol-Plus
  • Others
• Zambia Cholera Vaccines Market, By End User
• • Hospitals & Clinics
  • Research & Academic Laboratories
  • Others
• Top Companies in the Zambia Cholera Vaccines Market:
• • Biovac Inc 
  • Valneva SE.
  • EMERGENT
  • Astellas Pharma Inc
  • Sanofi
  • EUBIOLOGICS CO., LTD
  • Johnson & Johnson Services Inc.
  • Celldex Therapeutics.